viernes, 6 de diciembre de 2013

Transdermal absorption of memantin--eff... [Eur J Pharm Biopharm. 2012] - PubMed - NCBI

Transdermal absorption of memantin--eff... [Eur J Pharm Biopharm. 2012] - PubMed - NCBI


Eur J Pharm Biopharm. 2012 Sep;82(1):164-70. doi: 10.1016/j.ejpb.2012.06.005. Epub 2012 Jun 23.


Transdermal absorption of memantin--effect of chemical enhancers, iontophoresis, and role of enhancer lipophilicity.





Source


Instituto de Ciencias Biomédicas, Universidad CEU Cardenal Herrera, C/ Del Pozo S/N 46115, Alfara del Patriarca (Valencia), Spain.



Abstract



The transdermal administration of memantine may have advantages with respect to oral therapy when treating advanced stages of Alzheimer's disease. With the ultimate objective of administrating memantine through a transdermal patch, the absorption of the drug across skin was evaluated by means of in vitro permeation studies. The effect of several chemical enhancers was studied in order to enhance percutaneous absorption of the memantine. The iontophoretic transdermal transport of memantine hydrochloride using a current density of 0.5 mA/cm(2) was also investigated. Results demonstrated that pre-treatment of the skin with R-(+)-limonene, laurocapram, decenoic acid, or oleic acid produced a statistically significant increment in the transdermal flux of memantine hydrochloride with respect to the control. Iontophoresis exhibited the greatest ability to enhance the flux of drug with respect to the control; nevertheless, the results obtained with R-(+)-limonene indicate that this compound could be of great use as a percutaneous enhancer in a memantine transdermal delivery system. In this study, the relationship between enhancement activity and lipophilicity was also studied. Satisfactory correlations have been obtained between the optimum lipophilicity of the enhancer and n-octanol/water partition coefficients of drugs. This relationship is a very useful tool that could allow to reduce time and to optimize the selection of appropriate enhancers for transdermal formulations.
Copyright © 2012 Elsevier B.V. All rights reserved.



PMID:

22732268
[PubMed - indexed for MEDLINE]

No hay comentarios:

Publicar un comentario